

NC Medicaid and NC Health Choice Pharmacy Prior Approval Request for Growth Hormone – Children Less than 21 Years of Age

Beneficiary Information _____2. First Name: ______ Beneficiary Last Name: 4. Beneficiary Date of Birth: ______ 5. Beneficiary Gender: _____ 3. Beneficiary ID #: _____ Prescriber Information 6. Prescribing Provider NPI #: 7. Requester Contact Information - Name: ______ Phone #: _____ Ext. _____ Drug Information _____ 10. Quantity Per 30 Days: ___ _____ 9. Strength: _____ 8. Drug Name:___ 11. Length of Therapy (in days): □ up to 30 Days □ 60 Days □ 90 Days □ 120 Days □ 180 Days □ 365 Days Clinical Information FOR NON-PREFERRED DRUGS: COMPLETE THIS SECTION AS WELL AS BELOW. 2. ☐ Failed two preferred drug(s). List preferred drugs failed: ___ 2b. Or list reason why patient cannot try two preferred drugs: ___ 3. History of: ☐ Turners Syndrome ☐ Prader Willi Syndrome ☐ Craniopharyngioma in the last 2 years ☐ Panhypopituitarism in the last 2 years ☐ Cranial Irradiation in the last 2 years ☐ MRI History of Hypopituitarism list: ☐ Hypopituitarism \square Chronic Renal Insufficiency in the last 2 years \square SGA with IUGR ☐ Other: 4. Please check all that apply: ☐ Patient has a height velocity < 25th Percentile for Bone Age. Height Velocity: _ ☐ Patient has low serum levels of IGF-1 and IGFBP-3 IGF-1 Level: ______ IGFBP-3 Level: ____ ☐ Patient has other signs of hypopituitarism List: _____ ☐ Patient is an adequately nourished child with hypoglycemia and a low GH response to hypoglycemia ☐ Patient's height is < 3rd percentile for chronological age Height: Percentile: ☐ Birth weight and/or length more than 2 standard deviations below mean for gestational age with no catch up by age 2. ☐ History of GHD in the last 2 years. Is there a genetic cause? ____ ☐ Stim testing? Agent 1: _____ Agent 2: ____ Peak: ____ Ng/ml 5. Is the epiphysis open (if patient > 9 years old)? ☐ Yes ☐ No 6. Is the patient diagnosed with unexplained short statue with height > 2.25 standard deviations below mean for age, and bone age >2 standard deviations below mean, and low serum levels of IGF-1 and IGFBP-3?

Yes
No IGF-1 Level: _______ 7. Is the patient currently being treated? \square Yes \square No 7a. Growth rate over previous year: ______ 7b. Has the patient entered puberty? ☐ Yes ☐ No 8. Are IGF-1 and IGF-BP3 within age appropriate range? ☐ Yes ☐ No Results: _____ **Zorbitive only**: 9. Is there a history of short bowel syndrome in the last 2 years? ☐ **Yes** ☐ **No** Increlex only: 10. Check all that apply: ☐ History of GH product in last year ☐ GH resistance is caused by mutation in GH receptor of post GH receptor signaling pathway ☐ Patient has IGF-1 gene defects ☐ GH gene deletions and patient has developed neutralizing antibodies to GH ☐ Patient ht < 3 SD < mean and IGF-1 level < 3 SD < Mean and normal or elevated GH levels. Zorbitive only: 11. Is there a history of short bowel syndrome in the last 2 years? ☐ Yes ☐ No Signature of Prescriber:_____ ____ Date: ____

I certify that the information provided is accurate and complete to the best of my knowledge, and I understand that any falsification, omission, or concealment of material fact may subject me to civil or criminal liability.

(Prescriber Signature Mandatory)

DHB Pharmacy 20 02/25/21

Pharmacy PA Call Center: (866) 246-8505